Health Condition 1: null- BRVO with macular edema
Conditions
Interventions
Intervention1: ranibizumab and laser: treatment of brvo with macular edema with ranibizumab and laser
Control Intervention1: ranibizumab only: treatment of brvo with macular edema with ranibizumab onl
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosed case of BRVO with macular edema with evidence of capillary non perfusion 2. Macular edema involving center of fovea 3. BCVA at baseline- 3/60-6/18 by Snellenâ??s visual acuity 4. Mean central subfield thickness > 300 micrometer by OCT at baseline visit 5. Informed consent 6. Media clarity, pupillary dilatation and patient cooperation sufficient for fundus photography
Exclusion criteria
Exclusion criteria: 1. other ocular diseases like AMD eyes, diabetic retinopathy, disc pallor 2. recent CVA, MI or major ischemic event 3 months preceding baseline visit 3. known sensitivity to any anti-VEGF drugs and sodium fluorescein 4. previous macular or pan retinal photocoagulation 5.previous anti-VEGF treatment 6.no consent 7.patient not willing for follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA ( snellens visual acuity and ETDRS)Timepoint: 1 month, 3 months, 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| OCT number of ranibizumab injections contrast sensitivityTimepoint: 1 month, 3 months, 6 months | — |
Countries
India
Contacts
Public ContactSiddhi Goel
AIIMS
Outcome results
None listed